Abeona Therapeutics INC Form 4 insider transactions

Joseph Vazzano, CFO of Abeona Therapeutics, disposed of 1,055 shares of common stock on July 21, 2024, to cover tax obligations related to vesting restricted stock.

Director Donald A. Wuchterl reports acquisition of Abeona Therapeutics shares.

Brendan M. O'Malley, SVP and General Counsel of Abeona Therapeutics, acquired 102,689 shares of common stock on July 8, 2024, as part of a restricted stock grant.

Joseph Walter Vazzano, CFO of Abeona Therapeutics, acquired 155,200 shares of common stock on July 8, 2024, as reported in a Form 4 filing with the SEC.

Christine Berni Silverstein, a director of Abeona Therapeutics, acquired 23,611 shares of common stock on July 8, 2024.

Director Mark Alvino reports acquiring 23,611 shares of Abeona Therapeutics common stock and disposing of an unspecified amount on July 8, 2024.

Director Michael Amoroso acquired 23,611 shares of Abeona Therapeutics on July 8, 2024.

Director Faith L. Charles acquired 23,611 shares of Abeona Therapeutics Inc. on July 8, 2024.

Director Leila Alland acquired 23,611 shares of Abeona Therapeutics common stock on July 8, 2024.

Abeona Therapeutics' CEO, Vishwas Seshadri, acquired 424,000 shares of common stock on July 8, 2024, bringing his total holdings to 922,936 shares.

Mark Alvino, a director of Abeona Therapeutics, sold 25,890 shares of common stock on June 18, 2024, to cover tax obligations associated with vesting of restricted stock awards.

Christine Berni Silverstein, a director of Abeona Therapeutics, sold shares of common stock to cover tax obligations associated with the vesting of restricted stock awards.

Joseph Vazzano, CFO of Abeona Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock.

Abeona Therapeutics CEO Vishwas Seshadri reports disposition of shares to cover tax obligations upon vesting of restricted stock.

Brendan M. O'Malley, SVP and General Counsel of Abeona Therapeutics, sold shares to cover tax obligations upon vesting of restricted stock.

Brendan O'Malley, SVP and General Counsel of Abeona Therapeutics, reports the disposition of 92 shares of common stock to cover tax obligations upon vesting of restricted stock on March 31, 2024.

Abeona Therapeutics' CEO, Vishwas Seshadri, reports a transaction involving the surrender of restricted stock to cover tax obligations upon vesting.

Director Leila Alland purchased 11,000 shares of Abeona Therapeutics (ABEO) at $4.709 per share on May 16, 2024.

Adage Capital Management, along with Robert Atchinson and Phillip Gross, report acquisition of pre-funded warrants in Abeona Therapeutics, potentially increasing their stake but limited by ownership restrictions.

Abeona Therapeutics CEO Vishwas Seshadri recently purchased 10,000 shares of the company's common stock at a price of $3.2 per share.

Director Faith L. Charles purchased 7,550 shares of Abeona Therapeutics Inc. at $3.28 per share on April 26, 2024, increasing their total holdings to 78,323 shares.

Brendan M. O'Malley, SVP and General Counsel of Abeona Therapeutics, recently purchased 8,600 shares of the company's common stock at a price of $3.24 per share.

Joseph Walter Vazzano, CFO of Abeona Therapeutics, purchased 5,608 shares of common stock at an average price of $3.14 per share on April 25, 2024.

Chief Financial Officer of Abeona Therapeutics, Joseph Vazzano, disposed of 703 shares of common stock to cover tax obligations related to vesting restricted stock.

Brendan O'Malley, SVP and General Counsel of Abeona Therapeutics, reported the disposition of 183 shares of common stock to cover tax obligations upon vesting of restricted stock on March 4, 2024.